Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Five Biotechs Poised to Advance Their Rare Disease Programs [2022 updated] On the cusp of rare disease day, we’re checking in with Maryland biotech companies at the forefront of rare [….]
Cerecor Announces $43 Million Deal with AYTU BioScience to Sell Pediatric Portfolio and Advance Towards NDA
Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, [….]
